Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

What is the Role of Biomarker Testing in GVHD?

July 25th 2022

A brief review of the evolving utilization of biomarker testing in acute graft versus host disease, particularly for prognostic evaluation.

Women in Oncology: Leukemia Therapies in Humans, for Humans

July 24th 2022

Judith Karp, MD, Azra Raza, MD, and Michelle M. Le Beau, PhD, discuss their proudest career accomplishments, including the investigation of potential treatments using a patient’s first cancerous cell, advances in cytogenetics, and a rational design for clinical trials involving cell cytokinetics..

Women in Oncology: Finding Strength and Support in Community

July 24th 2022

Judith Karp, MD, Azra Raza, MD,, and Michelle M. Le Beau, PhD, discuss how their gender has shaped their professional lives, from working as some of the only female clinical faculty at their institutions to being compared to their male colleagues and denied opportunities when working independently from men.

Therapeutic Sequencing and Bridging in DLBCL

July 22nd 2022

Optimizing approaches to therapeutic sequencing in relapsed/refractory DLBCL.

Treating Patients Who Relapse or Progress on CAR T-Cell Therapy

July 22nd 2022

Drs Nowakowski and Gordon discuss treatment options after disease relapse on CAR T-cell therapy.

BiTEs, CAR T-Cell Therapy, and ADCs Offer Variety of Lymphoma Treatment Options, But Questions Remain

July 22nd 2022

An influx of bispecific T-cell engagers, CAR T-cell therapies, and antibody-drug conjugates have revolutionized the treatment of hematologic malignancies; however, with several options in the sandbox, accessibility and unexplored clinical questions present challenges for optimal integration of these options into treatment.

ASCT No Longer Suitable for the Majority of Patients with DLBCL

July 22nd 2022

Most patients with diffuse large B-cell lymphoma do not derive significant benefit from treatment with autologous stem cell transplantation and better therapeutic options are currently available for this population.

Zanubrutinib Displays Improved Efficacy Vs Orelabrutinib in Relapsed/Refractory CLL/SLL and MCL

July 22nd 2022

Zanubrutinib demonstrated a significant improvement in progression-free survival compared with orelabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma or mantle cell lymphoma.

Dr. Brody on Second-Line CAR T-cell Therapy in DLBCL

July 22nd 2022

Joshua Brody, MD, discusses the significance of CAR T-cell therapies being used in earlier treatment lines in patients with diffuse large B-cell lymphoma who relapse within their first year of receiving chemotherapy.

Dr. D’Angelo on Emerging Therapies in DLBCL

July 21st 2022

Christopher R. D’Angelo, MD, discusses emerging therapies in diffuse large B-cell lymphoma.

Westin and Sehn Carve Out the Role of CAR T-Cell Therapy and Transplant in Primary Refractory DLBCL

July 21st 2022

CAR T-cell therapy, autologous stem cell transplant, and novel agents each have a role to play in the second-line management of patients with primary refractory diffuse large B-cell lymphoma, according to Jason Westin, MD, MS, FACP, and Laurie H. Sehn, MD, MPH.

Pooled Real-World Data Support Earlier Line Use of IRd in Relapsed/Refractory Multiple Myeloma

July 21st 2022

A pooled analysis of the INSIGHT MM, UVEA-IXA, and REMIX observational studies found that real-world outcomes with ixazomib/lenalidomide/dexamethasone were consistent with those reported in the TOURMAILINE-MM1 study.

Increased Treatment Efficacy in p53-Mutated MCL Remains Elusive

July 21st 2022

Tycel Jovelle Phillips, MD, outlines the reasons why p53-mutated mantle cell lymphoma is difficult to treat and discusses potential future directions for the treatment of this subgroup of patients.

Eltanexor Gets FDA Fast Track Status and Orphan Medicinal Product Designation in Europe for MDS

July 21st 2022

Eltanexor has been granted a fast track designation from the FDA and an orphan medicinal product designation from the European Commission for use as a potential therapeutic option in patients with myelodysplastic syndromes.

FDA Grants Fast Track and Rare Pediatric Disease Designations to WU-CART-007 in R/R T-ALL and LBL

July 21st 2022

The FDA has granted fast track and rare pediatric disease designations to the CAR T-cell therapy WU-CART-007 for the treatment of patients with relapsed/refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.

Selinexor Combo Approved in Europe for Multiple Myeloma After at Least 1 Prior Therapy

July 21st 2022

The European Commission granted a full marketing authorization to selinexor in combination with once-weekly bortezomib and low-dose dexamethasone for the treatment of adults with multiple myeloma who have received at least 1 previous therapy.

Multidisciplinary Team Approach Is Ideal for irAE Management in Follicular Lymphoma

July 21st 2022

Immune checkpoint inhibitor therapy in relapsed follicular lymphoma can induce immune-related adverse events which can be difficult to diagnose and manage.

Thrombopoietin Receptor Agonists in Pediatric Immune Thrombocytopenia

July 21st 2022

Shared insight on thrombopoietin receptor agonist (TPO-RA) use in the pediatric setting of immune thrombocytopenia management.

Chronic Immune Thrombocytopenia: Considerations for Fostamatinib Therapy

July 21st 2022

Expert perspectives on the selection and use of fostamatinib as second-line therapy in patients with immune thrombocytopenia.

Adding Novel Agents to Established Chemotherapy Regimens Key to Expanding Frontline Treatment of Classic Hodgkin Lymphoma

July 21st 2022

Alison J. Moskowitz, MD, explains how the addition of novel agents to established chemotherapy regimens could further shift the frontline treatment paradigm for classic Hodgkin lymphoma.